The broader market reversed on Monday, recovering from the steep losses witnessed on Friday, on hopes of an interest rate cut ...

Shares of Kenvue, the maker of Tylenol and Benadryl, could be a remedy for investors left aching by the stock market’s selloff, analysts at Wolfe Research say. The company has struggled since it ...

In April 2025, it was announced that Dan Loeb’s Third Point took at stake in Kenvue. The stock reacted positively. Loeb is not the only activist on board. TOMS Capital is also pushing for changes.

According to Citadel's most recent 13F filing, the firm bought 18,736,591 shares of Kenvue (KVUE -0.32%) stock during the second quarter -- increasing its position by 5,848%.

Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand ...

Shares of Kenvue Inc. KVUE advanced 1.53% to $23.96 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.63% to 5,604.14 ...

PwC went on to add that IPO activity saw a strong increase in 2024, with 61 traditional IPOs garnering more than $26.4 billion YTD, which was in line with the combined total number of IPOs in 2022 ...

Shares of Kenvue Inc. KVUE shed 2.08% to $23.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kenvue wasn’t one of them.

On this episode of Stock Movers: - Coinbase (COIN) share are gaining after Argus Research Corp initiated coverage of the stock with a recommendation of buy and a $400 price target.